phosphoribosyl-n-formylglycineamide has been researched along with Cancer of Lung in 1 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Pemetrexed represents the first antifolate cancer drug to be approved by the Food and Drug Administration in 20 years; it is currently in widespread use for first line therapy of mesothelioma and non-small cell lung cancer." | 3.75 | Therapeutics by cytotoxic metabolite accumulation: pemetrexed causes ZMP accumulation, AMPK activation, and mammalian target of rapamycin inhibition. ( Heyer, CL; Moran, RG; Racanelli, AC; Rothbart, SB, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Racanelli, AC | 1 |
| Rothbart, SB | 1 |
| Heyer, CL | 1 |
| Moran, RG | 1 |
1 other study available for phosphoribosyl-n-formylglycineamide and Cancer of Lung
| Article | Year |
|---|---|
Therapeutics by cytotoxic metabolite accumulation: pemetrexed causes ZMP accumulation, AMPK activation, and mammalian target of rapamycin inhibition.
Topics: Adenylate Kinase; Aminoimidazole Carboxamide; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; | 2009 |